1. Home
  2. VTEX vs ABUS Comparison

VTEX vs ABUS Comparison

Compare VTEX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$4.11

Market Cap

755.3M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.27

Market Cap

836.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTEX
ABUS
Founded
1999
2005
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
755.3M
836.0M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
VTEX
ABUS
Price
$4.11
$4.27
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $5.57
N/A
AVG Volume (30 Days)
769.7K
★ 6.3M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
N/A
★ 0.84
Revenue
N/A
★ $14,083,000.00
Revenue This Year
$9.79
$1,208.75
Revenue Next Year
$7.62
N/A
P/E Ratio
$43.33
★ $5.17
Revenue Growth
N/A
★ 128.21
52 Week Low
$2.84
$3.50
52 Week High
$4.62
$5.45

Technical Indicators

Market Signals
Indicator
VTEX
ABUS
Relative Strength Index (RSI) 61.29 39.63
Support Level $3.51 $4.12
Resistance Level $4.20 $4.57
Average True Range (ATR) 0.16 0.17
MACD 0.03 0.00
Stochastic Oscillator 60.71 27.33

Price Performance

Historical Comparison
VTEX
ABUS

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: